Latest Commercial Agreements News

Firebrick Pharma has received a $293,000 R&D Tax Incentive payment linked to $673,000 of eligible development spending on new Nasodine products. The non-dilutive cash arrives as the company broadens its product range and pursues approvals in additional markets.

Critica has produced high-purity mixed rare earth oxide and iron concentrate samples from its Jupiter project, giving potential counterparties physical products to evaluate. The milestone follows flowsheet improvements including stronger recovery, higher concentrate grades and lower sulphuric acid consumption, but commercial specifications and project economics remain unresolved.

Rhythm Biosciences has completed the first phase of transferring its ColoSTAT blood test to an independent NHS laboratory in England. The milestone supports its international laboratory-partnership strategy, but clinical validation and NHS adoption remain ahead.

Memphasys has signed a three-year exclusive distribution agreement covering the Czech Republic, Slovakia and Kazakhstan, with minimum purchases worth approximately A$674,000. The deal expands Felix’s European footprint while adding dedicated commercial leadership in the region.

FireFly Metals has turned a year of aggressive drilling into a substantially larger, higher-confidence Green Bay resource, backed by an August PEA and fresh funding. The next test is execution: feasibility, permits, construction decisions and the capital required to build a mine.

Emyria has presented its regulated Australian psychedelic-treatment experience to the US FDA, putting clinical delivery systems rather than drug development at the centre of its US ambitions. The appearance raises the company’s profile, but does not yet disclose regulatory approval, a commercial agreement or a financial commitment.

Sparc Technologies has reported a 25% reduction in corrosion creep after adding HydroGraph’s Fractal Graphene to its ecosparc protective coating. The result strengthens the commercial case, but a definitive supply agreement remains conditional on longer testing due in November.

Simble Solutions’ NanoSensor has detected UV-A, UV-B, UV-C and visible wavelengths in initial laboratory testing, moving the platform into formal benchmarking. The result is an encouraging technical step, but commercial progress still depends on performance data, prototypes and customer validation.

Forrestania Resources has signed agreements giving it access to up to 2 million tonnes of third-party ore and a five-year framework for future mining services. Initial supply is expected from stockpiles at MEGA Resources’ Taipan open pit, although volumes, timing and financial returns remain uncommitted.

Vanadium Resources has secured an oversubscribed A$1.0 million placement to advance studies, site work, offtake discussions and project financing for its planned V-Iron Plant in South Africa. The raise gives VR8 fresh development capital, but the project still depends on a scoping study, binding commercial agreements and a much larger funding package.

Emyria has secured a limited in-person speaking position at a US FDA hearing examining how psychedelic medicines could be delivered safely and at scale. The appearance gives the ASX-listed company a regulatory platform, but does not represent FDA approval, funding or a commercial agreement.

Optiscan Imaging has reached an 84-case milestone in its live digital pathology study with Australian Clinical Labs, testing the InForm platform across a broad range of tissue types and disease settings. The data may support future regulatory submissions and commercial discussions, but the announcement does not disclose diagnostic accuracy metrics or regulatory approval.